These results supported the hypothesis that sPD-L1 binds to PD-1 on circulating T cells in peripheral blood before cytotoxic T cells reach the tumor site, thus impairing T cell-mediated antitumor immune activity and resulting in a poor treatment response for patients with high sPD-L1 levels. Here, SPDL1 is linked to neoplasm.